Tools

LEADER 02780cam a2200577 a 4500

001 ocn614271791;

003 OCoLC;

005 20141212053258.0;

008 100511s2010 dcua b 000 0 eng ;

010 a| 2010020157;

016 7 a| 1015307862| DNLM;

020 a| 9780309151290 (pbk.);

020 a| 0309151295 (pbk.);

020 a| 9780309151306 (pdf);

020 a| 0309151309 (pdf);

029 1 a| NLMb| 101530786;

029 1 a| CDXb| 13257201;

029 1 a| AU@b| 000045597998;

035 a| (Sirsi) o614271791;

035 a| (OCoLC)614271791;

042 a| pcc;

049 a| NEHH;

050 00 a| R853.B54b| E93 2010;

060 10 a| QW 541b| E917 2010;

082 00 a| 610.282| 22;

245 00 a| Evaluation of biomarkers and surrogate endpoints in chronic disease /c| Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, Board on Health Care Services, Board on Health Sciences Policy, Food and Nutrition Board, Institute of Medicine ; Christine M. Micheel and John R. Ball, editors.;

300 a| xx, 314 pages :b| illustrations ;c| 23 cm;

336 a| text2| rdacontent;

337 a| unmediated2| rdamedia;

338 a| volume2| rdacarrier;

504 a| Includes bibliographical references.;

505 0 a| Review : evaluating and regulating biomarker use -- The biomarker evaluation process -- Case studies-- Strengthening evidence-based regulation.;

520 a| "Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process."--Publisher's description.;

650 0 a| Biochemical markersx| Evaluation.=| ^A160152;

650 0 a| Chronic diseases.=| ^A332500;

650 12 a| Biomarkers=| ^A926094;

650 22 a| Chronic Disease.=| ^A917815;

650 22 a| Evidence-Based Practice.=| ^A1001678;

700 1 a| Micheel, Christine.=| ^A1021842;

700 1 a| Ball, John,d| 1944-=| ^A944951;

710 2 a| Institute of Medicine (U.S.).b| Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease.=| ^A1021245;

994 a| C0b| TEF;

938 a| Coutts Information Servicesb| COUTn| 13257201c| 32.00 GBP;

938 a| YBP Library Servicesb| YANKn| 3412963;

590 a| Laupus-WCP;

096 a| QW 541 E92 2010;

596 a| 4;

998 a| 2321044;

999 a| QW 541 E92 2010w| NLMc| 1i| 31740082675913d| 7/27/2011e| 10/25/2010f| 2/7/2011g| 2l| HSLBKm| HSLn| 1p| $51.70r| Ys| Yt| HBKu| 10/18/2010x| BOOKz| HSTACKSo| .STAFF. hdjr;

Evaluation of biomarkers and surrogate endpoints in chronic disease / Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, Board on Health Care Services, Board on Health Sciences Policy, Food and Nutrition Board, Institute of Medicine ; Christine M. Micheel and John R. Ball, editors.

Other author	Micheel, Christine.
Other author	Ball, John, 1944-
Other author	Institute of Medicine (U.S.). Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease.
Format	Book
Publication Info	Washington, D.C. : National Academies Press, ©2010.
Description	xx, 314 pages : illustrations ; 23 cm
Subjects	Biochemical markers--Evaluation. Chronic diseases. Biomarkers Chronic Disease. Evidence-Based Practice.

Contents	Review : evaluating and regulating biomarker use -- The biomarker evaluation process -- Case studies-- Strengthening evidence-based regulation.
Abstract	"Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process."--Publisher's description.
Local note	Laupus-WCP
Bibliography note	Includes bibliographical references.
LCCN	2010020157
ISBN	9780309151290 (pbk.)
ISBN	0309151295 (pbk.)
ISBN	9780309151306 (pdf)
ISBN	0309151309 (pdf)

Availability

Library	Location	Call Number	Status	Item Actions
Laupus	Books - Stacks	QW 541 E92 2010	✔ Available	Place Hold

Click here for more information about this title

Availability